person · Reporting owner

Powell Andrew Kenneth William

Disclosed activity across 5 companies

Tapewire entity: 90276
SEC CIK: 0001304113

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARS Pharmaceuticals, Inc.SBTX · Entity 883	Director	June 10, 2022	June 13, 2022
Aclaris Therapeutics, Inc.ACRS · Entity 5041	Director	June 01, 2024	June 04, 2024
LIFECORE BIOMEDICAL, INC. \DE\LNDC · Entity 6447	Director	June 04, 2022	June 07, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARS Pharmaceuticals, Inc.

Report date June 10, 2022 · Filed June 13, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2032-06-09	Direct	18,000	Reported balance After 2022-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-10 · Grant · Acquired 18,000 · Balance 18,000 F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Aclaris Therapeutics, Inc.

Report date June 01, 2024 · Filed June 04, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	33,523	Reported balance After 2024-06-01 transaction · row 1 1 source row Row 1 · 2024-06-01 · Exercise / conversion · Acquired 4,660 · Balance 33,523 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-06-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-06-01 · Exercise / conversion · Disposed 4,660 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2: The shares underlying these restricted stock units vested on June 1, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2: The shares underlying these restricted stock units vested on June 1, 2024.

LIFECORE BIOMEDICAL, INC. \DE\

Report date June 04, 2022 · Filed June 07, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	27,477	Reported balance After 2022-06-04 transaction · row 1 1 source row Row 1 · 2022-06-04 · Grant · Acquired 7,059 · Balance 27,477 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.
Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2022-06-04	Direct	0	Reported balance After 2022-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-06-04 · Exercise / conversion · Disposed 7,059 · Balance 0 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2: The restricted stock units were granted on June 4, 2021. F3: The restricted stock units vested on June 4, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.

F2: The restricted stock units were granted on June 4, 2021.

F3: The restricted stock units vested on June 4, 2022.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MEDIVATION, INC.

Report date September 28, 2016 · Filed September 30, 2016

Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-09-28 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2016-09-28 · Other · Disposed 5,597 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-09-28 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2016-09-28 · Disposition to issuer · Disposed 22,920 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.17 · Expires 2025-06-01	Direct	Reported balance After 2016-09-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-09-28 · Disposition to issuer · Disposed 40,860 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.77 · Expires 2026-02-28	Direct	Reported balance After 2016-09-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-09-28 · Disposition to issuer · Disposed 38,530 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-02-18	Direct	Reported balance After 2016-09-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-09-28 · Disposition to issuer · Disposed 14,474 · Balance 0 F4: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels. F5: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.

F2: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger.

F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

F4: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels.

F5: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger.

Synthorx, Inc.

Report date January 23, 2020 · Filed January 24, 2020

Section 16 reporting ended · disclosed 2020-01-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2028-12-18	Direct	0	Reported balance After 2020-01-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-01-23 · Disposition to issuer · Disposed 27,015 · Balance 0 F1: This option, which provided for vesting of the shares in equal monthly installments over a three year period such that the option would be fully vested on December 19, 2021, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,458,810.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.40 · Expires 2029-06-06	Direct	0	Reported balance After 2020-01-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-23 · Disposition to issuer · Disposed 6,389 · Balance 0 F2: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $355,228.40, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).

Filing footnotes · ownership attribution and instrument terms

F1: This option, which provided for vesting of the shares in equal monthly installments over a three year period such that the option would be fully vested on December 19, 2021, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,458,810.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).

F2: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $355,228.40, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 15, 2017 Filed Jun 16, 2017 19:45 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (right to buy) · Derivative	8,000	$0.00 Strike: $24.58	$0.00	Disclosure SEC source: 0001209191-17-040672 · doc4.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: The shares underlying this option vest in twelve equal monthly installments through June 15, 2018, subject to the reporting person's continuous service as of such vesting date. Read SEC document
January 25, 2017 Filed Jan 26, 2017 17:37 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (right to buy) · Derivative	16,000	$0.00 Strike: $27.30	$0.00	Disclosure SEC source: 0001209191-17-005760 · doc4.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2027-01-24 F1 · derivative.exercise_date: This option will vest and become exercisable in 36 equal monthly installments through January 25, 2020, subject to the reporting person's continuous service as of such vesting dates. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:54 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerPerformance-Based Restricted Stock Units · Derivative	14,474	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001209191-16-143389 · doc4.xml · derivative · entry 5 Powell Andrew Kenneth William · CIK 0001304113 · SVP, General Counsel & Crp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,474 shares Expires 2020-02-18 F4 · shares: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels. F5 · price: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger. F5 · derivative.exercise_date: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger. F4 · derivative.underlying_shares: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:54 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	38,530	Not disclosed Strike: $35.77	Not disclosed	Disclosure SEC source: 0001209191-16-143389 · doc4.xml · derivative · entry 4 Powell Andrew Kenneth William · CIK 0001304113 · SVP, General Counsel & Crp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,530 shares Expires 2026-02-28 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:54 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	40,860	Not disclosed Strike: $64.17	Not disclosed	Disclosure SEC source: 0001209191-16-143389 · doc4.xml · derivative · entry 3 Powell Andrew Kenneth William · CIK 0001304113 · SVP, General Counsel & Crp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,860 shares Expires 2025-06-01 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:54 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerCommon Stock	22,920	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-16-143389 · doc4.xml · nonDerivative · entry 2 Powell Andrew Kenneth William · CIK 0001304113 · SVP, General Counsel & Crp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2 · shares: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. F1 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:54 UTC	MEDIVATION, INC. MDVN · Entity 181987	OtherCommon Stock	5,597	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-16-143389 · doc4.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · SVP, General Counsel & Crp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F1 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.